These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21494091)

  • 21. An overview of pharmaceutical cocrystals as intellectual property.
    Trask AV
    Mol Pharm; 2007; 4(3):301-9. PubMed ID: 17477544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
    Gorlin DI
    Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Emerging and early stage company showcase pre-conference symposium.
    Razvi ES
    IDrugs; 2005 Oct; 8(10):796-8. PubMed ID: 16254794
    [No Abstract]   [Full Text] [Related]  

  • 24. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical patent challenges--time for reassessment?
    Glass G
    Nat Rev Drug Discov; 2004 Dec; 3(12):1057-62. PubMed ID: 15573104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the opportunities for pharmaceutical manufacturers in emerging markets.
    Anderson T; Olson J; Sobelman D
    J Manag Care Pharm; 2009 Jun; 15(5):396-402. PubMed ID: 19496636
    [No Abstract]   [Full Text] [Related]  

  • 28. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.
    Kesselheim AS
    AAPS J; 2007 Aug; 9(3):E306-11. PubMed ID: 17915832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Delivery 2007--New technologies, partnering and strategies for the future.
    Stevenson L
    IDrugs; 2007 Jun; 10(6):388-90. PubMed ID: 17642001
    [No Abstract]   [Full Text] [Related]  

  • 31. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
    Angeli F
    Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The publishing and patenting strategies of successful university spinoffs in the biopharmaceutical industry.
    Erden Z
    Drug Discov Today; 2017 Jan; 22(1):5-9. PubMed ID: 27634342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intellectual property protection for plant-related inventions in Europe.
    Fleck B; Baldock C
    Nat Rev Genet; 2003 Oct; 4(10):834-8. PubMed ID: 14526379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the private sector in biotechnology: research and development.
    Feisee L
    Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
    [No Abstract]   [Full Text] [Related]  

  • 36. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney.
    Melethil S
    AAPS J; 2005 Oct; 7(3):E723-8. PubMed ID: 16353948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How drug life-cycle management patent strategies may impact formulary management.
    Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
    Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US courts struggle with new patent infringement standards.
    Jones P
    Nat Biotechnol; 2004 Apr; 22(4):461-3. PubMed ID: 15085803
    [No Abstract]   [Full Text] [Related]  

  • 39. Intellectual property protection of plant biotechnology inventions.
    Sechley KA; Schroeder H
    Trends Biotechnol; 2002 Nov; 20(11):456-61. PubMed ID: 12413819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IP issues facing researchers by Gino D'Oca.
    Almarsson O; Angiolini M; Baell J; Giardina G; Ingham A; Hughes A; Pevarello P; Sindelar R
    Pharm Pat Anal; 2012 May; 1(2):129-35. PubMed ID: 24236778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.